Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma : Episode 4
Elranatamab Dosing Strategies: Implications for Community Practice
Panelists discuss how teclistamab administration and outcomes vary between academic and community settings, highlighting the need for standardized monitoring protocols, staff education, and communication frameworks to ensure consistent patient care and safety across different practice environments.
Video content above is prompted by the following:
- Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-Up Doses in Academic vs Community Settings
- Are there strategies that could help optimize administration and monitoring across these different settings to ensure safety and efficacy?
- MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
- Do these findings impact your selection of patients for elranatamab, particularly in community settings?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
